

# Anna Alisi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1072763/anna-alisi-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228 papers	7,592 citations	50 h-index	77 g-index
266 ext. papers	9,203 ext. citations	5.5 avg, IF	6 L-index

#	Paper	IF	Citations
228	Circulating microRNAs as novel non-invasive biomarkers of paediatric celiac disease and adherence to gluten-free diet.. <i>EBioMedicine</i> , <b>2022</b> , 76, 103851	8.8	2
227	Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage.. <i>Nutrition and Metabolism</i> , <b>2022</b> , 19, 9	4.6	
226	Epigenetic remodelling in human hepatocellular carcinoma.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 107	12.8	4
225	Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.. <i>Hepatology Communications</i> , <b>2022</b> ,	6	2
224	Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease.. <i>Frontiers in Pediatrics</i> , <b>2022</b> , 10, 885576	3.4	
223	The Role of Phytosterols in Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , <b>2022</b> , 14, 2187	6.7	1
222	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2021</b> ,	7.9	6
221	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 364	12.8	3
220	Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1154-1158	3.3	13
219	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. <i>EBioMedicine</i> , <b>2021</b> , 65, 103249	8.8	1
218	Pediatric Non-Alcoholic Fatty Liver Disease Is Affected by Genetic Variants Involved in Lifespan/Healthspan. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2021</b> , 73, 161-168	2.8	1
217	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
216	Cytokine expression patterns in hospitalized children with Bordetella pertussis, Rhinovirus or co-infection. <i>Scientific Reports</i> , <b>2021</b> , 11, 10948	4.9	1
215	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 775-782	13.4	50
214	Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. <i>Liver International</i> , <b>2021</b> , 41, 788-798.	7.9	5
213	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 20-30	13.4	24
212	Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. <i>Obesity Surgery</i> , <b>2021</b> , 1	3.7	1

211	Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 864-873	18.8	27
210	PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 1564-1572	4.5	0
209	TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, e7-e8	3.3	2
208	The anti-inflammatory effects of hydroxytyrosol and vitamin e on paediatric NAFLD. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, e42-e43	3.3	2
207	Complications, morbidity and mortality of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 111S, 154170	12.7	113
206	GDF11 induces mild hepatic fibrosis independent of metabolic health. <i>Aging</i> , <b>2020</b> , 12, 20024-20046	5.6	6
205	The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19. <i>Drugs</i> , <b>2020</b> , 80, 941-946	12.1	22
204	The pharmacological treatment of nonalcoholic fatty liver disease in children. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 1219-1227	3.8	2
203	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2020</b> , 1865, 158765	5	4
202	A Lipidomic Signature Complements Stemness Features Acquisition in Liver Cancer Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
201	Noninvasive diagnostic tools for pediatric NAFLD: where are we now?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 1035-1046	4.2	3
200	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 113, 154413	12.7	16
199	HDL cholesterol protects from liver injury in mice with intestinal specific LXR $\alpha$ activation. <i>Liver International</i> , <b>2020</b> , 40, 3127-3139	7.9	5
198	From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1590-1592	13.4	0
197	Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
196	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). <i>Clinical Epigenetics</i> , <b>2020</b> , 12, 126	7.7	7
195	The Contribution of the Adipose Tissue-Liver Axis in Pediatric Patients with Nonalcoholic Fatty Liver Disease after Laparoscopic Sleeve Gastrectomy. <i>Journal of Pediatrics</i> , <b>2020</b> , 216, 117-127.e2	3.6	5
194	FKltho gene variation is associated with liver damage in children with NAFLD. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 411-419	13.4	27

193	The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease. <i>Journal of Pediatrics</i> , <b>2019</b> , 211, 72-77.e4	3.6	8
192	Association of Bright Liver With the PNPLA3 I148M Gene Variant in 1-Year-Old Toddlers. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2163-2170	5.6	4
191	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. <i>Hepatology</i> , <b>2019</b> , 70, 142-153	11.2	23
190	Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?. <i>Antioxidants and Redox Signaling</i> , <b>2019</b> , 30, 1325-1330	8.4	11
189	Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2019</b> , 39, 2317-2329	7.9	14
188	Letter to the Editor: Focal Adhesion Kinase/ $\beta$ Catenin Network May Act as a Regulator of Hepatocellular Carcinoma Epigenetics. <i>Hepatology</i> , <b>2019</b> , 70, 1494-1495	11.2	2
187	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 802-810	13.4	18
186	The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	9
185	NAFLD in children: new genes, new diagnostic modalities and new drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 517-530	24.2	105
184	Is obesity in childhood protective for breast cancer in young women?. <i>Translational Cancer Research</i> , <b>2019</b> , 8, 1012-1013	0.3	
183	Obesity and Nonalcoholic Fatty Liver Disease in Children <b>2019</b> , 209-222		0
182	Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH. <i>Scientific Reports</i> , <b>2019</b> , 9, 2045	4.9	27
181	Maternal Intake of n-3 Polyunsaturated Fatty Acids During Pregnancy Is Associated With Differential Methylation Profiles in Cord Blood White Cells. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 1050	4.5	6
180	The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?. <i>Antioxidants and Redox Signaling</i> , <b>2019</b> , 31, 127-133	8.4	17
179	Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. <i>Liver International</i> , <b>2018</b> , 38, 342-349	7.9	24
178	Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2018</b> , 28, 71-76	4.5	4
177	Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201566	3.7	2
176	Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. <i>Archives of Medical Science</i> , <b>2018</b> , 14, 81-87	2.9	55

175	In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children. <i>Pediatric Research</i> , <b>2018</b> , 84, 696-703	3.2	6
174	The exposure to uteroplacental insufficiency is associated with activation of unfolded protein response in postnatal life. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198490	3.7	14
173	Laparoscopic Sleeve Gastrectomy Improves Nonalcoholic Fatty Liver Disease-Related Liver Damage in Adolescents by Reshaping Cellular Interactions and Hepatic Adipocytokine Production. <i>Journal of Pediatrics</i> , <b>2018</b> , 194, 100-108.e3	3.6	17
172	PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	11
171	Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. <i>Frontiers in Genetics</i> , <b>2018</b> , 9, 443	4.5	2
170	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2018</b> , 67, 635-642	2.8	6
169	A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. <i>Nutrition Research</i> , <b>2018</b> , 58, 1-16	4	21
168	Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. <i>Hepatology</i> , <b>2017</b> , 65, 451-464	11.2	354
167	Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1031-1036	13.4	94
166	Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. <i>Applied Physiology, Nutrition and Metabolism</i> , <b>2017</b> , 42, 948-954	3	33
165	Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2017</b> , 65, 150-155	2.8	13
164	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1277-1286	0.7	22
163	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. <i>Cell Death and Differentiation</i> , <b>2017</b> , 24, 889-902	12.7	36
162	The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. <i>Mediators of Inflammation</i> , <b>2017</b> , 2017, 8162421	4.3	85
161	Nonalcoholic Fatty Liver Disease in Italian Children with Down Syndrome: Prevalence and Correlation with Obesity-Related Features. <i>Journal of Pediatrics</i> , <b>2017</b> , 189, 92-97.e1	3.6	13
160	The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. <i>Journal of Pediatrics</i> , <b>2017</b> , 180, 31-37.e2	3.6	73
159	Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	44
158	Arterial Stiffness, Thickness and Association to Suitable Novel Markers of Risk at the Origin of Cardiovascular Disease in Obese Children. <i>International Journal of Medical Sciences</i> , <b>2017</b> , 14, 711-720	3.7	13

157	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2016</b> , 53, 106-20	9.4	28
156	Early Glucose Derangement Detected by Continuous Glucose Monitoring and Progression of Liver Fibrosis in Nonalcoholic Fatty Liver Disease: An Independent Predictive Factor?. <i>Hormone Research in Paediatrics</i> , <b>2016</b> , 85, 29-34	3.3	6
155	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 860-8	3.3	14
154	High concentrations of H <sub>2</sub> O <sub>2</sub> trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes. <i>Experimental and Molecular Pathology</i> , <b>2016</b> , 100, 199-206	4.4	6
153	Pediatric liver diseases: current challenges and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 255-65	4.2	13
152	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , <b>2016</b> , 150, 1798-810	13.3	84
151	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 393-403	4.2	17
150	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168216	3.7	56
149	Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors. <i>Current Drug Metabolism</i> , <b>2016</b> , 17, 308-16	3.5	26
148	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157246	3.7	41
147	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. <i>Hepatology</i> , <b>2016</b> , 63, 787-98	11.2	70
146	Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2016</b> , 63, 745-53	11.2	45
145	Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 909-13	3.3	18
144	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , <b>2015</b> , 61, 506-14	11.2	311
143	Nonalcoholic fatty liver disease: a challenge for pediatricians. <i>JAMA Pediatrics</i> , <b>2015</b> , 169, 170-6	8.3	82
142	Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 462-70	0.7	33
141	Arginase 1: a potential marker of a common pattern of liver steatosis in HCV and NAFLD children. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1207-8	13.4	4
140	Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. <i>International Journal of Obesity</i> , <b>2015</b> , 39, 1118-25	5.5	43



139	Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 2353-9	4	17
138	Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR- $\alpha$ <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2015</b> , 1, 646-663.e4	7.9	104
137	Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. <i>Thorax</i> , <b>2015</b> , 70, 769-81	7.3	34
136	Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. <i>Clinical Endocrinology</i> , <b>2015</b> , 83, 656-62	3.4	59
135	Targeting FGF19 binding to its receptor system: a novel therapeutic approach for hepatocellular carcinoma. <i>Hepatology</i> , <b>2015</b> , 62, 1324	11.2	1
134	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2015</b> , 61, 85-90	2.8	31
133	Thyroid Hormones and their Metabolites: Biological Roles and Association with Non-Alcoholic Fatty Liver Disease. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , <b>2015</b> , 15, 43-59		3
132	OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 815721	4.3	28
131	LPS-induced TNF- $\alpha$ factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. <i>Oncotarget</i> , <b>2015</b> , 6, 41434-52	3.3	78
130	Activation of an endothelial Notch1-Jagged1 circuit induces VCAM1 expression, an effect amplified by interleukin-1 $\beta$ <i>Oncotarget</i> , <b>2015</b> , 6, 43216-29	3.3	20
129	Macrophages and fibrosis in adipose tissue are linked to liver damage and metabolic risk in obese children. <i>Obesity</i> , <b>2014</b> , 22, 1512-9	8	21
128	Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. <i>Genes and Nutrition</i> , <b>2014</b> , 9, 392	4.3	38
127	NASH and the Cross-Talk Between the Gut and Liver. <i>Current Pediatrics Reports</i> , <b>2014</b> , 2, 211-217	0.7	1
126	Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. <i>Journal of Pediatrics</i> , <b>2014</b> , 165, 92-8	3.6	26
125	Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. <i>European Journal of Endocrinology</i> , <b>2014</b> , 170, 547-53	6.5	73
124	A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2014</b> , 58, 632-6	2.8	58
123	Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e88005	3.7	94
122	MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 15079-86	5.6	40

121	Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. <i>Expert Review of Molecular Diagnostics</i> , <b>2014</b> , 14, 763-71	3.8	19
120	Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 21202-14	6.3	59
119	Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 684-711	6.3	21
118	Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity?. <i>Pediatric Obesity</i> , <b>2014</b> , 9, e99-e102	4.6	35
117	Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 2501-11	4	6
116	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1276-85	6.1	269
115	Non-alcoholic fatty liver and metabolic syndrome in children: a vicious circle. <i>Hormone Research in Paediatrics</i> , <b>2014</b> , 82, 283-9	3.3	28
114	Commentary: FGF21 holds promises for treating obesity-related insulin resistance and hepatosteatosis. <i>Endocrinology</i> , <b>2014</b> , 155, 343-6	4.8	6
113	Effect of fructose and 3,5-diiodothyronine (3,5-T(2)) on lipid accumulation and insulin signalling in non-alcoholic fatty liver disease (NAFLD)-like rat primary hepatocytes. <i>Hormone and Metabolic Research</i> , <b>2014</b> , 46, 333-40	3.1	14
112	Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 556-60	3.3	115
111	Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 16443-51	5.6	24
110	Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1526-31	0.7	83
109	A 360-degree overview of paediatric NAFLD: recent insights. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 1218-29	13.4	120
108	Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2013</b> , 23, 1066-70	4.5	93
107	Engineered Escherichia coli as new source of flavonoids and terpenoids. <i>Food Research International</i> , <b>2013</b> , 54, 1084-1095	7	15
106	Daclatasvir: a promising triple therapy for children with chronic hepatitis C. <i>Lancet Infectious Diseases, The</i> , <b>2013</b> , 13, 17-8	25.5	1
105	Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. <i>Liver International</i> , <b>2013</b> , 33, 79-85	7.9	68
104	Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 543-51	3.3	60



103	ADAR enzyme and miRNA story: a nucleotide that can make the difference. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 22796-816	6.3	31
102	EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 24154-68	6.3	39
101	Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 24706-25	6.3	69
100	Paediatric nonalcoholic fatty liver disease. <i>Current Opinion in Gastroenterology</i> , <b>2013</b> , 29, 279-84	3	17
99	The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. <i>Journal of Medicinal Food</i> , <b>2013</b> , 16, 957-60	2.8	49
98	Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2013</b> , 7, 601-4	4.2	5
97	Retinoids counteract insulin resistance and liver steatosis: what's the potential mechanism?. <i>Hepatology</i> , <b>2013</b> , 58, 1185	11.2	0
96	Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2013</b> , 56, 370-5	2.8	28
95	Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e67160	3.7	69
94	Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis. <i>Journal of Nutritional Biochemistry</i> , <b>2012</b> , 23, 169-78	6.3	13
93	Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. <i>Nutrition</i> , <b>2012</b> , 28, 722-6	4.8	29
92	Energy expenditure and insulin sensitivity evaluation in obese children affected by hepatosteatosis. <i>Pediatric Obesity</i> , <b>2012</b> , 7, e14-7	4.6	9
91	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , <b>2012</b> , 30, 49-56	4.4	46
90	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2012</b> , 9, 152-61	24.2	79
89	Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2012</b> , 56, 2142-53	11.2	108
88	Nonalcoholic fatty liver in children and adolescents: an overview. <i>Journal of Adolescent Health</i> , <b>2012</b> , 51, 305-12	5.8	33
87	Metabolic syndrome and alcohol abuse: a potential hepatocarcinogenic mix in adolescents. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 204; author reply 204-5	6.9	2
86	Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 1312-8	13.4	60

85	Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. <i>Annals of Medicine</i> , <b>2012</b> , 44, 29-40	1.5	78
84	Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma. <i>Hepatology</i> , <b>2012</b> , 56, 1589	11.2	4
83	Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e42259	3.7	34
82	Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2012</b> , 2, 132	5.9	36
81	I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology. <i>Hepatology</i> , <b>2012</b> , 56, 791	11.2	20
80	Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatoesteatosis in rats. <i>International Journal of Molecular Sciences</i> , <b>2012</b> , 13, 2276-89	6.3	40
79	Transient elastography and serum biomarkers: two-step screening methods for liver fibrosis in non-alcoholic fatty liver disease before liver biopsy. <i>Expert Opinion on Medical Diagnostics</i> , <b>2012</b> , 6, 377-80		2
78	Circulating miRNA profiling to identify biomarkers of dysmetabolism. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 729-42	2.3	12
77	Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. <i>International Journal of Oncology</i> , <b>2012</b> , 41, 117-24	4.4	4
76	LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2012</b> , 54, 588-93	2.8	46
75	Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e44147	3.7	19
74	Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 143-6	3.3	9
73	Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. <i>Archives of Disease in Childhood</i> , <b>2011</b> , 96, 350-3	2.2	195
72	Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 956-63	13.4	11
71	Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 647-653	13.4	27
70	Effect of treatment with polyunsaturated fatty acids on HCV- or diet-induced fatty liver. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 1325-6; author reply 1326	13.4	
69	Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. <i>Vaccine</i> , <b>2011</b> , 29, 4654-6	4.1	17
68	Role of Fatty Liver Disease in Childhood Obesity <b>2011</b> , 221-230		

67	Dual role of survivin in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2011</b> , 31, 1416-7; author reply 1417	7.9	2
66	Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. <i>Laboratory Investigation</i> , <b>2011</b> , 91, 283-93	5.9	161
65	Recent advances in biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis: the role of lipid analysis/profiling. <i>Clinical Lipidology</i> , <b>2011</b> , 6, 427-436		1
64	Transient elastography for assessment of fibrosis in paediatric liver disease. <i>Pediatric Radiology</i> , <b>2011</b> , 41, 1232-8	2.8	30
63	Supplementation of monounsaturated and polyunsaturated fatty acids in non-alcoholic fatty liver disease and metabolic syndrome. <i>Lipids</i> , <b>2011</b> , 46, 389-90	1.6	1
62	Metabolic syndrome and nonalcoholic steatohepatitis recurrence after liver transplantation in children. <i>Liver Transplantation</i> , <b>2011</b> , 17, 620-1	4.5	1
61	Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis. <i>Hepatology</i> , <b>2011</b> , 53, 372-3	11.2	12
60	Activation of the endotoxin/toll-like receptor 4 pathway: the way to go from nonalcoholic steatohepatitis up to hepatocellular carcinoma. <i>Hepatology</i> , <b>2011</b> , 53, 1069	11.2	4
59	The wide spectrum of hepatic iron overload. <i>Hepatology</i> , <b>2011</b> , 53, 1057-8; author reply 1058-9	11.2	2
58	Hepatitis C virus therapeutics: editing enzymes promising therapeutic targets?. <i>Hepatology</i> , <b>2011</b> , 54, 742; author reply 742-3	11.2	
57	Human hepatic stellate cells are liver-resident antigen-presenting cells. <i>Hepatology</i> , <b>2011</b> , 54, 1107	11.2	4
56	Hepatic stellate cell proliferation: a potential role of protein kinase R. <i>Hepatology</i> , <b>2011</b> , 54, 1484-5; author reply 1485-6	11.2	1
55	Liver fibrosis in paediatric liver diseases. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 259-68	2.5	19
54	Current treatment for nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2141-2; author reply 2142	4	2
53	Expert opinion on current therapies for nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1901-11	4	12
52	Intrauterine growth retardation and nonalcoholic Fatty liver disease in children. <i>International Journal of Endocrinology</i> , <b>2011</b> , 2011, 269853	2.7	54
51	Indirect markers of fibrosis in chronic liver diseases: Is aspartate transaminase-to-platelet ratio (APRI) a useful test?. <i>Hepatitis Monthly</i> , <b>2011</b> , 11, 558-9	1.8	1
50	Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. <i>Pediatric Research</i> , <b>2010</b> , 67, 665-70	3.2	52

49	Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. <i>Translational Research</i> , <b>2010</b> , 156, 229-34	11	50
48	Hepatitis C virus and nonalcoholic Fatty liver disease: similar risk factors for necroinflammation, fibrosis, and cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2010</b> , 8, 97; author reply 97	6.9	1
47	Microarray technology: a promising tool in nutrigenomics. <i>Critical Reviews in Food Science and Nutrition</i> , <b>2010</b> , 50, 693-8	11.5	16
46	Functions and therapeutic value of focal adhesion kinase signaling during hepatocellular carcinoma development and progression. <i>Hepatology</i> , <b>2010</b> , 51, 1092-3	11.2	
45	Nonalcoholic fatty liver disease in children. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , <b>2010</b> , 13, 397-402	3.8	29
44	Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2010</b> , 50, 645-9	2.8	105
43	Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , <b>2010</b> , 26, 471-6	4.4	67
42	Toll-like receptor 4: a starting point for proinflammatory signals in fatty liver disease. <i>Hepatology</i> , <b>2010</b> , 51, 714-5	11.2	6
41	Natural approach against lipotoxic traffic in nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2010</b> , 52, 399	11.2	
40	The link between hepatosteatosis and cells of the immune system. <i>Hepatology</i> , <b>2010</b> , 51, 1472; author reply 1472-3	11.2	
39	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2010</b> , 52, 1274-80	11.2	200
38	Novel Tween 20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 3021-5	2.9	20
37	Fatty Liver Disease <b>2010</b> , 201-222		1
36	Association between type two diabetes and non-alcoholic fatty liver disease in youth. <i>Annals of Hepatology</i> , <b>2009</b> , 8, S44-S50	3.1	29
35	A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. <i>Archives of Disease in Childhood</i> , <b>2009</b> , 94, 801-5	2.2	60
34	Antioxidant effects of natural bioactive compounds. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3063-73	3.3	110
33	Pediatric nonalcoholic fatty liver disease in 2009. <i>Journal of Pediatrics</i> , <b>2009</b> , 155, 469-74	3.6	106
32	The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. <i>BMC Medicine</i> , <b>2009</b> , 7, 21	11.4	98

31	Profiling microRNA expression: a snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis. <i>Hepatology</i> , <b>2009</b> , 49, 706-7	11.2	3
30	Portal inflammation as index of steatohepatitis in children with nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2009</b> , 50, 659	11.2	3
29	Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2009</b> , 50, 2048-9; author reply 2049-50	11.2	17
28	Psychosocial condition after liver transplantation in children: review of the literature from 2006 to 2008. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 3779-83	1.1	5
27	Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 749-52	3.3	37
26	Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2009</b> , 7, 575-9	6.9	57
25	Glutathionylation of p65NF-kappaB correlates with proliferating/apoptotic hepatoma cells exposed to pro- and anti-oxidants. <i>International Journal of Molecular Medicine</i> , <b>2009</b> , 24, 319-26	4.4	16
24	Liver fibrosis and therapeutic strategies: the goal for improving metabolism. <i>Current Drug Targets</i> , <b>2009</b> , 10, 505-12	3	22
23	Association between type two diabetes and non-alcoholic fatty liver disease in youth. <i>Annals of Hepatology</i> , <b>2009</b> , 8 Suppl 1, S44-50	3.1	18
22	PKR is a novel functional direct player that coordinates skeletal muscle differentiation via p38MAPK/AKT pathways. <i>Cellular Signalling</i> , <b>2008</b> , 20, 534-42	4.9	21
21	Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. <i>Clinical Therapeutics</i> , <b>2008</b> , 30, 1168-76	3.5	97
20	Viral hepatitis B: established and emerging therapies. <i>Current Medicinal Chemistry</i> , <b>2008</b> , 15, 930-9	4.3	15
19	Involvement of PI3K in HCV-related lymphoproliferative disorders. <i>Journal of Cellular Physiology</i> , <b>2008</b> , 214, 396-404	7	17
18	Risk of severe liver disease in NAFLD with normal ALT levels: a pediatric report. <i>Hepatology</i> , <b>2008</b> , 48, 2087-8; author reply 2088	11.2	41
17	Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. <i>Pediatric Endocrinology Reviews</i> , <b>2008</b> , 6, 241-7	1.1	105
16	Hepatitis C virus (HCV): an RNA virus with a pro-oncogenic potential. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S46-51	3.3	7
15	Hepatitis C virus core protein enhances B lymphocyte proliferation. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39 Suppl 1, S72-5	3.3	12
14	Bioinformatics as tool to identify gene/protein-pathways associated with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , <b>2007</b> , 46, 1306; author reply 1306-7	11.2	2

13	Molecular genetics of NASH: the role of polymorphisms. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 868-9; author reply 870-1	13.4	5
12	Molecular pathogenesis of nonalcoholic steatohepatitis: today and tomorrow. <i>American Journal of Pathology</i> , <b>2007</b> , 171, 712-3; author reply 713	5.8	2
11	Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. <i>Nutrition Reviews</i> , <b>2007</b> , 65, 550-3	6.4	7
10	Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 10983-9	5.4	38
9	HCV-Related Transformation and New Therapeutic Strategies: An Update. <i>Current Cancer Therapy Reviews</i> , <b>2006</b> , 2, 41-56	0.4	5
8	Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. <i>Journal of Cellular Physiology</i> , <b>2005</b> , 205, 25-31	7	20
7	Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis. <i>Cellular Physiology and Biochemistry</i> , <b>2005</b> , 15, 69-76	3.9	33
6	Thyroid hormones regulate DNA-synthesis and cell-cycle proteins by activation of PKCalpha and p42/44 MAPK in chick embryo hepatocytes. <i>Journal of Cellular Physiology</i> , <b>2004</b> , 201, 259-65	7	36
5	Treatment with EGF increases the length of S-Phase after partial hepatectomy in rat, changing the activities of cdks. <i>Cellular Physiology and Biochemistry</i> , <b>2003</b> , 13, 239-48	3.9	12
4	Physical and functional interaction between HCV core protein and the different p73 isoforms. <i>Oncogene</i> , <b>2003</b> , 22, 2573-80	9.2	55
3	The G-quadruplex/helicase world as a potential antiviral approach against COVID-19		2
2	Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways		1
1	Plasma lipidomics identifies a signature of NAFLD in children that couples with cardiometabolic outcomes in adults		2